The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.
About 8 healthy men will join the study, so that at least 6 people complete it. Each participant will drink a single dose of OD-001 as a liquid. This will be done on an empty stomach, so each participant will be asked not to eat for a period of time beforehand.
The medicine contains a small amount of a radioactive "tracer" (carbon-14). The tracer lets researchers follow the medicine and its breakdown products through your body. The amount of radioactivity is small and carefully limited. After the dose, researchers will collect samples such as blood, urine and stool. These will show how much of the medicine is recovered and what it turns into in the body.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Kelly Bourdon
- 電話番号:857-393-6160
- メール:clinicaltrials@odysseytx.com
研究場所
-
-
-
Ruddington、イギリス
- 募集
- Quotient Sciences
-
コンタクト:
- Study Coordinator
- 電話番号:+44 (0)115 974 9000
- メール:clinicaltrials@odysseytx.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 30 to 65 years inclusive at the time of signing informed consent
- Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of the procedure Healthy male participants according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs, single 12-lead ECGs, and laboratory safety tests without any clinically significant abnormalities as measured at screening. ECGs and vital signs to be re-checked at pre-dose.
- Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
- Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).
Exclusion Criteria:
- Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
- History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, UC, CD, Irritable Bowel Syndrome or malabsorption syndrome that may impair bioavailability, and neurological or psychiatric disorder
- Participants who are unable to take oral medication.
- Acute diarrhea, constipation or vomiting in the 7 days before the predicted Day 1. If screening occurs >7 days before Day 1his criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:[14C]OD-001
oral solution |
[14C]OD-001 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Mass balance recovery of total radioactivity in all excreta: CumAe
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Rate of elimination of [14C]OD-001 in excreta by Ae
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by %Ae
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by Cum%Ae by interval
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of treatment-emergent adverse events
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Percentage of [14C] total radioactivity OD-001 metabolites in excreta
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Tmax of OD-001 in blood, total radioactivity in blood and plasma
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Cmax of OD-001 in blood, total radioactivity in blood and plasma
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
AUC0-last of OD-001 in blood, total radioactivity in blood and plasma
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
T1/2 of OD-001 in blood, total radioactivity in blood and plasma
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal clinical laboratory test results
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal electrocardiograms (ECGs)
時間枠:Day 1 to Day 8
|
Day 1 to Day 8
|
協力者と研究者
捜査官
- 主任研究者:Sharan Sidhu, MBChB, BAO, MRCS, MFPM、Quotient Sciences
- スタディディレクター:Anthony Opipari、Odyssey Therapeutics, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。